Eupraxia Pharmaceuticals reports Q2 results

Aug. 12, 2022 8:46 AM ETEupraxia Pharmaceuticals Inc. (EPRXF), EPRX:CABy: Pranav Ghumatkar, SA News Editor
  • Eupraxia Pharmaceuticals press release (OTCPK:EPRXF): Q2 net loss of $6.3 million.
  • The Company had a cash and short-term investments balance of $35.5 million as at June 30, 2022. Management believes it has sufficient resources to fund the Company through to the fourth quarter of 2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.